Trial Profile
A Multicenter, Open Label, Single Ascending Dose Study to Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2014
Price :
$35
*
At a glance
- Drugs Tesidolumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Novartis
- 01 Dec 2014 New trial record